Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis

J Neurooncol. 2013 Jun;113(2):277-84. doi: 10.1007/s11060-013-1107-5. Epub 2013 Mar 16.


Mutations in the gene encoding isocitrate dehydrogenase (IDH) have been identified in approximately 65-90 % of low-grade gliomas (LGGs). Various studies examining the relationship between IDH mutation with the clinical outcome in patients with LGGs have yielded inconclusive results. The purpose of the present meta-analysis of literature is to determine this effect. We conducted a meta-analysis of 10 studies (937 patients) that evaluated the correlation between IDH mutation and overall survival (OS). For the quantitative aggregation of the survival results, the IDH mutation effect was measured by hazard ratio (HR). Overall, the pooled HR was 0.585 (95 % CI, 0.376-0.911, p = 0.025, random effect model) for patients with IDH mutation vs patients without IDH mutation. IDH mutation was associated with better overall survival of LGGs. At least this trend was observed in our analysis.

Publication types

  • Meta-Analysis

MeSH terms

  • Adult
  • Biomarkers, Tumor / genetics*
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / mortality
  • Brain Neoplasms / pathology
  • Glioma / genetics*
  • Glioma / mortality
  • Glioma / pathology
  • Humans
  • Isocitrate Dehydrogenase / genetics*
  • Mutation / genetics*
  • Neoplasm Grading
  • Prognosis
  • Survival Rate


  • Biomarkers, Tumor
  • Isocitrate Dehydrogenase